CELLTRION-HEALTHCARE
19.8.2022 04:49:05 CEST | Business Wire | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin® , for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer.
“The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin® , Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.”
The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June 2022.
Today’s approval is based on the totality of evidence, including the phase III pivotal trial in patients with metastatic or recurrent non-squamous non-small cell lung cancer. Results showed that, as a first-line treatment, Vegzelma™ is highly similar to the reference product in terms of efficacy, safety and pharmacokinetics.2
Vegzelma™ (CT-P16) is Celltrion’s third oncology biosimilar approved for use in the EU, following the approval of Truxima® (biosimilar rituximab) and Herzuma® (biosimilar trastuzumab). Vegzelma™ was also filed for regulatory approval with the U.S. Food and Drug Administration (FDA) in September 2021. Approval is expected during the third quarter of 2022.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com
About Vegzelma™ (CT-P16, biosimilar bevacizumab)
Vegzelma™ is an anti-cancer monoclonal antibody treatment biosimilar to Avastin® (bevacizumab). Vegzelma™ is a recombinant humanised monoclonal antibody which binds to VEGF, the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1), and kinase insert domain receptor (KDR) (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.3 In the EU, Vegzelma™ is indicated for the treatment of patients with metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell carcinoma, ovarian cancer, advanced cervical cancer and metastatic breast cancer.
References
1 Avastin is a registered trademark of Genentech Inc.
2 Ohe Y et al., Randomized Phase III Study Comparing the Efficacy and Safety of CT-P16, a New Biosimilar, to Reference Bevacizumab (Avastin) In Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC). Proceedings: American Association for Cancer Research (AACR) Annual Meeting 2022; April 8-13, 2022 New Orleans, Louisiana.
3 European Medicines Agency Summary of Product Characteristics (SmPC), Avastin. Available at https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf [Last accessed August 2022].
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005324/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify Launches Global Air Travel Fraud Report Revealing Where Booking-Stage Pressure Is Most Concentrated22.4.2026 14:00:00 CEST | Press release
Q1 2026 analysis shows significant variation in prevented fraud rates by origin city, with higher concentrations across parts of Latin America, Africa, the Middle East, and South & Southeast Asia Accertify, a leading unified risk decisioning platform provider, today announced the release of its Global Air Travel Fraud Report: Q1 2026, a quarterly analysis examining how fraud risk in airline bookings varies by route origin across global markets. Based on more than 180 million airline booking transactions processed between January and March 2026, the report analyzes fraud rates by departure city as a proxy for route origin, offering airlines a practical view of where fraud prevention systems are intervening most frequently at the point of booking. The Q1 2026 findings show that fraud risk in airline bookings is unevenly distributed across markets, with meaningful differences emerging by region and by origin city. Routes originating in North America and Australia continue to exhibit consi
NetApp Strengthens its Collaboration with Google Cloud on Unified Google Cloud Storage for File and Block22.4.2026 14:00:00 CEST | Press release
Announced at Next ‘26, Flex Unified service for Google Cloud NetApp Volumes is now generally available NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today shared new innovations that help customers better leverage their enterprise data, by tapping into the benefits of AI with Google Cloud. Enterprises want to use their existing data for AI, but moving and managing that data across multiple environments is complex, slow, and expensive. NetApp is simplifying this with Google Cloud. With Google Cloud NetApp Volumes, customers can run enterprise applications, databases, and AI workloads in the cloud without rearchitecting or rebuilding their environments. “Customers can move their enterprise data, whether block or file, into Google Cloud NetApp Volumes easily, and once it’s there, they can use Google Cloud services, including for AI, directly on that data without needing to move or duplicate it again,” said Pravjit Tiwana, Senior Vice President and General Manager of
NetApp Partners with Google Cloud to Adopt AI-Driven Operations22.4.2026 14:00:00 CEST | Press release
Google Gemini Enterprise drives productivity for NetApp sales and product development NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a strategic evolution in its partnership with Google Cloud, which has enabled enterprises to drive AI innovation with their own data stored in the NetApp data platform. After seeing the productivity and innovation benefits customers experienced using Gemini Enterprise integrated with their data in Google Cloud NetApp Volumes, NetApp has adopted Gemini Enterprise to help increase productivity in its internal product development and sales operations. With the adoption of Google Cloud AI technologies, NetApp is expanding its leadership in enterprise-grade AI innovation, not just enabling AI workloads but acting as an AI practitioner. NetApp customers will benefit from the AI-powered gains in productivity and innovation. “AI is an imperative for enterprise success, and NetApp is committed to leading by example,” said Césa
ExaGrid Named a Finalist for the Storage Awards 202622.4.2026 14:00:00 CEST | Press release
ExaGrid Product Line, Partner Program, and Team Nominated in 16 Categories for “The Storries XXIII” ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 16 categories for the 23rd annual Storage Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422235829/en/ ExaGrid has become a finalist in the following categories: Storage Innovator of the Year Immutable Storage Company of the Year Storage Industry Champion – Commercial Storage Industry Champion – Marketing Channel Excellence Award AI Data Storage Innovator of the Year Cyber Resilient Storage Company of the Year Ransomware Product of the Year Data Protection Company of the Year Enterprise Backup Hardware Vendor of the Year Object Storage Vendor of the Year Storage Optimisation Compan
Samsung Biologics Union Holds First Rally, Warns of May 1 Strike22.4.2026 13:56:00 CEST | Press release
Union estimates about 2,200 participants at one-hour event outside Bio Campus 1 Samsung Biologics’ labor union held its first rally on Tuesday and said it would move ahead with a strike on May 1 if management continues to reject meaningful talks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422754766/en/ Union members gather at a rally organized by the Samsung Biologics labor union outside Bio Campus 1 in Songdo, Incheon, on April 22, ahead of a planned May 1 strike. The rally, held for about an hour outside the main gate of the company’s Bio Campus 1 in Songdo, drew about 2,200 participants, according to the union. The event marks an escalation in a labor dispute that union leaders say is no longer limited to a small number of bargaining items, but instead concerns broader questions about accountability and decision-making within the company. Park Jaesung, chair of the Samsung Biologics union, said management had faile
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom